Synopsis: Anupam Rasayan India Limited has highlighted significant growth opportunities arising from its proposed acquisition of Bliss GVS Pharma. The company expects revenue growth to recover to the 25–30 percent range in FY27 and has guided for EBITDA margins of 22–25 percent, supported by portfolio expansion and improved capacity utilization.
Anupam Rasayan’s proposed acquisition of Bliss GVS Pharma appears to be a strategically significant move that could strengthen the company’s long-term growth trajectory. Management believes the transaction offers substantial portfolio expansion opportunities while providing access to the pharmaceutical formulations segment, thereby reducing dependence on its traditional specialty chemicals business.
Anupam Rasayan India Limited has a total market capitalization of approximately Rs. 15,189.64 crore. The company’s shares were trading at Rs. 1334.20 apiece on the National Stock Exchange, up by 0.53 percent; the stock has declined around 2.47 percent over the last five sessions, while it has gone down about 1.02 percent in the 30 days, Whereas on a year-on-year basis it has increased nearly 30.24 percent, reflecting mixed overall performance. The stock’s 52-week high was Rs. 1415 and 52-week low was Rs. 993.20.
One of the key positives highlighted by the company is Bliss GVS Pharma’s valuation. According to management, the target company is trading at a discount compared to industry peers based on comparable valuation metrics, making the acquisition financially attractive. Additionally, Bliss is currently operating at capacity utilization levels of around 30 percent, indicating significant headroom for production ramp-up and operational improvement without requiring substantial new capital expenditure.
The management expects business growth to return to historical levels witnessed before FY24 and FY25, with revenue growth projected to recover to the 25–30 percent range in FY27. This guidance reflects confidence in the combined entity’s ability to capitalize on expanding opportunities across pharmaceuticals and specialty chemicals. The company has also guided for EBITDA margins in the range of 22–25 percent, suggesting expectations of improved profitability through better product mix, operating leverage, and acquisition synergies.
From a strategic standpoint, the acquisition diversifies Anupam Rasayan’s revenue base and expands its presence in the pharmaceutical value chain. The addition of Bliss GVS Pharma is expected to enhance the company’s product portfolio, broaden its customer reach, and create potential cross-selling opportunities across domestic and international markets. Such diversification could also reduce cyclicality associated with certain specialty chemical segments and improve earnings visibility over the long term.
The success of the transaction, however, will depend on effective integration and the company’s ability to realize expected synergies. Investors are likely to closely monitor capacity utilization improvements at Bliss, revenue growth, margin expansion, and the impact of the acquisition on Anupam Rasayan’s balance sheet and debt profile.
Anupam Rasayan India Limited is engaged in the manufacturing of specialty chemicals catering to industries such as pharmaceuticals, agrochemicals, polymers, personal care, and dyes. The company serves both domestic and international markets, exporting specialty chemical products to leading global customers through long-term business relationships.
With global supply-chain diversification trends, increasing outsourcing by multinational companies, and rising demand for advanced chemical solutions, the specialty chemicals industry remains well-positioned for growth. If executed successfully, the Bliss GVS Pharma acquisition could emerge as a key growth catalyst for Anupam Rasayan over the next few years.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
